Last Updated: May 11, 2026

Details for New Drug Application (NDA): 220089


✉ Email this page to a colleague

« Back to Dashboard


NDA 220089 describes PYLARIFY TRUVU, which is a drug marketed by Aphelion and is included in one NDA. There are six patents protecting this drug. Additional details are available on the PYLARIFY TRUVU profile page.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. One supplier is listed for this compound. Additional details are available on the piflufolastat f-18 profile page.
Summary for 220089
Tradename:PYLARIFY TRUVU
Applicant:Aphelion
Ingredient:piflufolastat f-18
Patents:6
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 220089
Generic Entry Date for 220089*:
⤷  Start Trial
Constraining patent/regulatory exclusivity:
⤷  Start Trial
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength1mCi/mL-120mCi/mL
Approval Date:Mar 6, 2026TE:RLD:Yes
Patent:⤷  Start TrialPatent Expiration:Jun 9, 2037Product Flag?YSubstance Flag?YDelist Request?
Patented Use:POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER
Patent:⤷  Start TrialPatent Expiration:Jun 9, 2037Product Flag?YSubstance Flag?YDelist Request?
Patented Use:POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER
Patent:⤷  Start TrialPatent Expiration:Jul 31, 2029Product Flag?YSubstance Flag?YDelist Request?
Patented Use:POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links